BI-1808

BioInvent's anti-TNFR2 antibody BI-1808 demonstrated a 50% response rate in cutaneous T-cell lymphoma patients, with one complete response and three partial responses among eight evaluable patients.

BioInvent International has secured FDA Fast Track Designation for BI-1808 in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma.

BioInvent's first-in-class anti-TNFR2 antibody BI-1808 receives FDA Orphan Drug Designation for treating T-cell lymphoma, providing development incentives and seven years of market exclusivity.

BioInvent's BI-1910 demonstrates stable disease in solid tumor patients as a single agent in Phase 1 dose escalation, with no notable adverse events.